STRO Sutro Biopharma, Inc.
Healthcare$27.38+7.08%ClosedMarket Cap: $265.0M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
-5.00
P/S
2.48
EV/EBITDA
-1.76
DCF Value
$-98.32
FCF Yield
-61.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
98.7%
Operating Margin
-115.5%
Net Margin
-154.2%
ROE
192.8%
ROA
-63.5%
ROIC
-64.3%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $14.5M | 91.2% | $-29.6M | $-38.5M | $— | — |
| Q4 null | $11.6M | 100.0% | $-33.7M | $-46.8M | $— | — |
| FY null | $102.5M | 92.9% | $-105.0M | $-191.1M | $— | — |
| Q3 null | $9.7M | 100.0% | $-48.5M | $-56.9M | $— | — |
| Q2 null | $63.7M | 100.0% | $-3.3M | $-11.5M | $— | — |
| Q1 null | $17.4M | 100.0% | $-68.5M | $-76.0M | $— | — |
| Q4 null | $14.8M | 100.0% | $-65.3M | $-72.4M | $— | — |
| FY null | $62.0M | 88.4% | $-238.5M | $-227.5M | $— | — |
| Q3 null | $8.5M | 100.0% | $-67.9M | $-48.8M | $— | — |
| Q2 null | $25.7M | 93.0% | $-48.7M | $-48.0M | $— | — |
| Q1 null | $13.0M | 86.5% | $-56.6M | $-58.2M | $— | — |
| Q4 2023 | $113.7M | 100.0% | $43.2M | $31.1M | $5.10 | — |